Fig. 2
From: Evaluation of dosing strategy for pembrolizumab for oncology indications
Predicted variation in pembrolizumab AUC exposure by body weight for weight-based (a) and fixed-dose (b) regimens (2800 replicate simulations): Horizontal dashed lines represent the range of exposures (5th percentile of 2 mg/kg Q3W and 95th percentile of 10 mg/kg Q2W) from dose regimens demonstrated to have comparable efficacy and tolerability in melanoma and NSCLC trials